Drug intelligence / Profile preview

89Zr-NY005

Development stage: Phase 1
Lead developer: Wuxi Nuoyu Pharmaceutical Technology
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

89Zr-NY005 is a diagnostic radiopharmaceutical consisting of an anti-CLDN18.2 monoclonal antibody labeled with zirconium-89. It is designed for PET imaging in patients with CLDN18.2-positive solid tumors to evaluate target expression and biodistribution.

Other names: 89Zr-labeled anti-CLDN18.2 monoclonal antibody89Zr-anti-CLDN18.2 mAbsZirconium-89-NY005Zirconium89-NY005Zirconium 89-NY005

Beyond the preview

Go deeper on 89Zr-NY005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 89Zr-NY005.

Explore the full profile